JP7038065B2 - 腫瘍溶解性ウイルス株 - Google Patents
腫瘍溶解性ウイルス株 Download PDFInfo
- Publication number
- JP7038065B2 JP7038065B2 JP2018555310A JP2018555310A JP7038065B2 JP 7038065 B2 JP7038065 B2 JP 7038065B2 JP 2018555310 A JP2018555310 A JP 2018555310A JP 2018555310 A JP2018555310 A JP 2018555310A JP 7038065 B2 JP7038065 B2 JP 7038065B2
- Authority
- JP
- Japan
- Prior art keywords
- virus
- strain
- tumor
- accession number
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 244000309459 oncolytic virus Species 0.000 title claims description 32
- 241000700605 Viruses Species 0.000 claims description 409
- 108090000623 proteins and genes Proteins 0.000 claims description 187
- 206010028980 Neoplasm Diseases 0.000 claims description 181
- 210000004027 cell Anatomy 0.000 claims description 105
- 230000037361 pathway Effects 0.000 claims description 73
- 102000004169 proteins and genes Human genes 0.000 claims description 67
- 239000003112 inhibitor Substances 0.000 claims description 52
- 241000700584 Simplexvirus Species 0.000 claims description 51
- 239000000556 agonist Substances 0.000 claims description 50
- 230000003308 immunostimulating effect Effects 0.000 claims description 46
- 238000000034 method Methods 0.000 claims description 46
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims description 45
- 101150027249 RL1 gene Proteins 0.000 claims description 45
- 230000014509 gene expression Effects 0.000 claims description 44
- 239000005557 antagonist Substances 0.000 claims description 41
- 201000011510 cancer Diseases 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 38
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 37
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 35
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 35
- 239000003814 drug Substances 0.000 claims description 34
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims description 33
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 33
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 27
- 239000002246 antineoplastic agent Substances 0.000 claims description 27
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 208000015181 infectious disease Diseases 0.000 claims description 26
- 230000028993 immune response Effects 0.000 claims description 25
- 230000004927 fusion Effects 0.000 claims description 22
- 230000001939 inductive effect Effects 0.000 claims description 22
- 108010029697 CD40 Ligand Proteins 0.000 claims description 19
- 102100032937 CD40 ligand Human genes 0.000 claims description 19
- 230000008488 polyadenylation Effects 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 16
- 238000012217 deletion Methods 0.000 claims description 15
- 230000037430 deletion Effects 0.000 claims description 15
- 102000003886 Glycoproteins Human genes 0.000 claims description 13
- 108090000288 Glycoproteins Proteins 0.000 claims description 13
- 101150085955 US11 gene Proteins 0.000 claims description 13
- 238000003780 insertion Methods 0.000 claims description 13
- 230000037431 insertion Effects 0.000 claims description 13
- 230000000174 oncolytic effect Effects 0.000 claims description 13
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 12
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 230000001105 regulatory effect Effects 0.000 claims description 11
- 230000010076 replication Effects 0.000 claims description 11
- -1 ICOS Proteins 0.000 claims description 10
- 101000597780 Mus musculus Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 claims description 10
- 238000001959 radiotherapy Methods 0.000 claims description 10
- 239000012275 CTLA-4 inhibitor Substances 0.000 claims description 9
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 9
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 9
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 9
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 230000004048 modification Effects 0.000 claims description 9
- 238000012986 modification Methods 0.000 claims description 9
- 102100034980 ICOS ligand Human genes 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 8
- 241000713869 Moloney murine leukemia virus Species 0.000 claims description 8
- 102000004473 OX40 Ligand Human genes 0.000 claims description 8
- 108010042215 OX40 Ligand Proteins 0.000 claims description 8
- 108700005077 Viral Genes Proteins 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000008685 targeting Effects 0.000 claims description 8
- 101150013553 CD40 gene Proteins 0.000 claims description 7
- 241000712079 Measles morbillivirus Species 0.000 claims description 7
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 7
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 claims description 6
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 6
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 6
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims description 6
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims description 6
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 6
- 108010043610 KIR Receptors Proteins 0.000 claims description 6
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims description 6
- 241000713821 Mason-Pfizer monkey virus Species 0.000 claims description 6
- 102100029198 SLAM family member 7 Human genes 0.000 claims description 6
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 6
- 230000002950 deficient Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 108010062802 CD66 antigens Proteins 0.000 claims description 5
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 5
- 102100031256 Cyclic GMP-AMP synthase Human genes 0.000 claims description 5
- 101710118064 Cyclic GMP-AMP synthase Proteins 0.000 claims description 5
- 101100195053 Human herpesvirus 1 (strain 17) RIR1 gene Proteins 0.000 claims description 5
- 239000012270 PD-1 inhibitor Substances 0.000 claims description 5
- 239000012668 PD-1-inhibitor Substances 0.000 claims description 5
- 239000012271 PD-L1 inhibitor Substances 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229940121655 pd-1 inhibitor Drugs 0.000 claims description 5
- 229940121656 pd-l1 inhibitor Drugs 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 206010064571 Gene mutation Diseases 0.000 claims description 4
- 108010074328 Interferon-gamma Proteins 0.000 claims description 4
- 102000008070 Interferon-gamma Human genes 0.000 claims description 4
- 241001559185 Mammalian rubulavirus 5 Species 0.000 claims description 4
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 4
- 108020004440 Thymidine kinase Proteins 0.000 claims description 4
- 230000002434 immunopotentiative effect Effects 0.000 claims description 4
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 229960003130 interferon gamma Drugs 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 241000713730 Equine infectious anemia virus Species 0.000 claims description 3
- 101710093458 ICOS ligand Proteins 0.000 claims description 3
- 102000002227 Interferon Type I Human genes 0.000 claims description 3
- 108010014726 Interferon Type I Proteins 0.000 claims description 3
- 108010065805 Interleukin-12 Proteins 0.000 claims description 3
- 108090000172 Interleukin-15 Proteins 0.000 claims description 3
- 108090000171 Interleukin-18 Proteins 0.000 claims description 3
- 108010002350 Interleukin-2 Proteins 0.000 claims description 3
- 229940125563 LAG3 inhibitor Drugs 0.000 claims description 3
- 101800001693 R-peptide Proteins 0.000 claims description 3
- 102100021696 Syncytin-1 Human genes 0.000 claims description 3
- 102100021742 Syncytin-2 Human genes 0.000 claims description 3
- 101710091284 Syncytin-2 Proteins 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 108010018844 interferon type III Proteins 0.000 claims description 3
- 108010074108 interleukin-21 Proteins 0.000 claims description 3
- 108090000237 interleukin-24 Proteins 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 230000001177 retroviral effect Effects 0.000 claims description 3
- 230000002269 spontaneous effect Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 108010037253 syncytin Proteins 0.000 claims description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 3
- 229940123189 CD40 agonist Drugs 0.000 claims description 2
- 108091006027 G proteins Proteins 0.000 claims description 2
- 102000030782 GTP binding Human genes 0.000 claims description 2
- 108091000058 GTP-Binding Proteins 0.000 claims description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 2
- 101710169105 Minor spike protein Proteins 0.000 claims description 2
- 101710081079 Minor spike protein H Proteins 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 108700014844 flt3 ligand Proteins 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 230000036961 partial effect Effects 0.000 claims description 2
- 208000003265 stomatitis Diseases 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 3
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 3
- 241000282693 Cercopithecidae Species 0.000 claims 1
- 241000282620 Hylobates sp. Species 0.000 claims 1
- 102000002698 KIR Receptors Human genes 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 description 85
- 230000003612 virological effect Effects 0.000 description 55
- 239000002773 nucleotide Substances 0.000 description 54
- 125000003729 nucleotide group Chemical group 0.000 description 54
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 30
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 230000000694 effects Effects 0.000 description 24
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 23
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 23
- 230000000259 anti-tumor effect Effects 0.000 description 23
- 238000000338 in vitro Methods 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 22
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 18
- 230000001976 improved effect Effects 0.000 description 18
- 241000894007 species Species 0.000 description 18
- 229940124597 therapeutic agent Drugs 0.000 description 18
- 239000003795 chemical substances by application Substances 0.000 description 17
- 241000701022 Cytomegalovirus Species 0.000 description 15
- 230000002147 killing effect Effects 0.000 description 15
- 230000002476 tumorcidal effect Effects 0.000 description 15
- 101000746372 Mus musculus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 14
- 239000013612 plasmid Substances 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 12
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 description 11
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 11
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 230000009089 cytolysis Effects 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 230000006801 homologous recombination Effects 0.000 description 10
- 238000002744 homologous recombination Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 10
- 230000029812 viral genome replication Effects 0.000 description 10
- 108010006025 bovine growth hormone Proteins 0.000 description 9
- 210000000481 breast Anatomy 0.000 description 9
- 230000030833 cell death Effects 0.000 description 9
- 230000000120 cytopathologic effect Effects 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 241001430294 unidentified retrovirus Species 0.000 description 9
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 230000003248 secreting effect Effects 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 108010074708 B7-H1 Antigen Proteins 0.000 description 7
- 102000008096 B7-H1 Antigen Human genes 0.000 description 7
- 208000004898 Herpes Labialis Diseases 0.000 description 7
- 102000002689 Toll-like receptor Human genes 0.000 description 7
- 108020000411 Toll-like receptor Proteins 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 238000003235 crystal violet staining Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 210000000496 pancreas Anatomy 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 238000010561 standard procedure Methods 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 description 6
- 230000007910 cell fusion Effects 0.000 description 6
- 239000002955 immunomodulating agent Substances 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000009885 systemic effect Effects 0.000 description 6
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 5
- 201000008808 Fibrosarcoma Diseases 0.000 description 5
- 241000700589 Herpes simplex virus (type 1 / strain 17) Species 0.000 description 5
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 5
- 102100033627 Killer cell immunoglobulin-like receptor 3DL1 Human genes 0.000 description 5
- 206010067152 Oral herpes Diseases 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- 101710116331 Sodium-dependent phosphate transporter 1 Proteins 0.000 description 5
- 102100029797 Sodium-dependent phosphate transporter 1 Human genes 0.000 description 5
- 102100035283 Tumor necrosis factor ligand superfamily member 18 Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 230000000091 immunopotentiator Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101100059511 Homo sapiens CD40LG gene Proteins 0.000 description 4
- 101710196623 Stimulator of interferon genes protein Proteins 0.000 description 4
- 230000005975 antitumor immune response Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 102000046157 human CSF2 Human genes 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 206010057248 Cell death Diseases 0.000 description 3
- 101100118093 Drosophila melanogaster eEF1alpha2 gene Proteins 0.000 description 3
- 101000658547 Escherichia coli (strain K12) Type I restriction enzyme EcoKI endonuclease subunit Proteins 0.000 description 3
- 101000658543 Escherichia coli Type I restriction enzyme EcoAI endonuclease subunit Proteins 0.000 description 3
- 101000658546 Escherichia coli Type I restriction enzyme EcoEI endonuclease subunit Proteins 0.000 description 3
- 101000658530 Escherichia coli Type I restriction enzyme EcoR124II endonuclease subunit Proteins 0.000 description 3
- 101000658540 Escherichia coli Type I restriction enzyme EcoprrI endonuclease subunit Proteins 0.000 description 3
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 3
- 101000658545 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Type I restriction enyme HindI endonuclease subunit Proteins 0.000 description 3
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 102000017578 LAG3 Human genes 0.000 description 3
- 101150030213 Lag3 gene Proteins 0.000 description 3
- 206010025323 Lymphomas Diseases 0.000 description 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 3
- 101000658548 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaIXP endonuclease subunit Proteins 0.000 description 3
- 101000658542 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIIP endonuclease subunit Proteins 0.000 description 3
- 101000658529 Methanocaldococcus jannaschii (strain ATCC 43067 / DSM 2661 / JAL-1 / JCM 10045 / NBRC 100440) Putative type I restriction enzyme MjaVIIP endonuclease subunit Proteins 0.000 description 3
- 101001042773 Staphylococcus aureus (strain COL) Type I restriction enzyme SauCOLORF180P endonuclease subunit Proteins 0.000 description 3
- 101000838760 Staphylococcus aureus (strain MRSA252) Type I restriction enzyme SauMRSORF196P endonuclease subunit Proteins 0.000 description 3
- 101000838761 Staphylococcus aureus (strain MSSA476) Type I restriction enzyme SauMSSORF170P endonuclease subunit Proteins 0.000 description 3
- 101000838758 Staphylococcus aureus (strain MW2) Type I restriction enzyme SauMW2ORF169P endonuclease subunit Proteins 0.000 description 3
- 101001042566 Staphylococcus aureus (strain Mu50 / ATCC 700699) Type I restriction enzyme SauMu50ORF195P endonuclease subunit Proteins 0.000 description 3
- 101000838763 Staphylococcus aureus (strain N315) Type I restriction enzyme SauN315I endonuclease subunit Proteins 0.000 description 3
- 101000838759 Staphylococcus epidermidis (strain ATCC 35984 / RP62A) Type I restriction enzyme SepRPIP endonuclease subunit Proteins 0.000 description 3
- 101000838756 Staphylococcus saprophyticus subsp. saprophyticus (strain ATCC 15305 / DSM 20229 / NCIMB 8711 / NCTC 7292 / S-41) Type I restriction enzyme SsaAORF53P endonuclease subunit Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 230000002519 immonomodulatory effect Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002601 intratumoral effect Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 2
- 101000653768 Homo sapiens Sodium-dependent phosphate transporter 1 Proteins 0.000 description 2
- 101000597779 Homo sapiens Tumor necrosis factor ligand superfamily member 18 Proteins 0.000 description 2
- 101000764263 Homo sapiens Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 2
- 241000005822 Human endogenous retrovirus W Species 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 101000764258 Mus musculus Tumor necrosis factor ligand superfamily member 4 Proteins 0.000 description 2
- 101000638253 Mus musculus Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 229930012538 Paclitaxel Natural products 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000007699 co-inhibitory pathway Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 102000053830 human TNFSF18 Human genes 0.000 description 2
- 102000051450 human TNFSF4 Human genes 0.000 description 2
- 230000005746 immune checkpoint blockade Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000015788 innate immune response Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N kynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000003865 nucleic acid synthesis inhibitor Substances 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229960001592 paclitaxel Drugs 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 230000005909 tumor killing Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102000006734 Beta-Globulins Human genes 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 235000005078 Chaenomeles speciosa Nutrition 0.000 description 1
- 240000000425 Chaenomeles speciosa Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 description 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 101001042049 Human herpesvirus 1 (strain 17) Transcriptional regulator ICP22 Proteins 0.000 description 1
- 101000999690 Human herpesvirus 2 (strain HG52) E3 ubiquitin ligase ICP22 Proteins 0.000 description 1
- 101150090364 ICP0 gene Proteins 0.000 description 1
- 101150076998 ICP34.5 gene Proteins 0.000 description 1
- 101150027427 ICP4 gene Proteins 0.000 description 1
- 101150102264 IE gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000859077 Mus musculus Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101100179071 Mus musculus Icoslg gene Proteins 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 101100369989 Mus musculus Tnfaip3 gene Proteins 0.000 description 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- YGACXVRLDHEXKY-WXRXAMBDSA-N O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 Chemical compound O[C@H](C[C@H]1c2c(cccc2F)-c2cncn12)[C@H]1CC[C@H](O)CC1 YGACXVRLDHEXKY-WXRXAMBDSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229940123752 RNA synthesis inhibitor Drugs 0.000 description 1
- 101150023114 RNA1 gene Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 241001068263 Replication competent viruses Species 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000012246 gene addition Methods 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 108010084724 gibbon ape leukemia virus receptor Proteins 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 102000046492 human ICOSLG Human genes 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000037841 lung tumor Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 101710130522 mRNA export factor Proteins 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003281 pleural cavity Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000009790 rate-determining step (RDS) Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 208000013718 rectal benign neoplasm Diseases 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/763—Herpes virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16633—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16641—Use of virus, viral particle or viral elements as a vector
- C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1600382.4A GB201600382D0 (en) | 2016-01-08 | 2016-01-08 | Engineered virus |
| GBGB1600380.8A GB201600380D0 (en) | 2016-01-08 | 2016-01-08 | Modified virus |
| GB1600381.6 | 2016-01-08 | ||
| GBGB1600381.6A GB201600381D0 (en) | 2016-01-08 | 2016-01-08 | Virus strain |
| GB1600382.4 | 2016-01-08 | ||
| GB1600380.8 | 2016-01-08 | ||
| PCT/GB2017/050037 WO2017118865A1 (en) | 2016-01-08 | 2017-01-09 | Oncolytic virus strain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019500909A JP2019500909A (ja) | 2019-01-17 |
| JP2019500909A5 JP2019500909A5 (enExample) | 2020-01-30 |
| JP7038065B2 true JP7038065B2 (ja) | 2022-03-17 |
Family
ID=57796748
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555311A Active JP7038664B2 (ja) | 2016-01-08 | 2017-01-09 | 操作された腫瘍溶解性ウイルス |
| JP2018555310A Active JP7038065B2 (ja) | 2016-01-08 | 2017-01-09 | 腫瘍溶解性ウイルス株 |
| JP2018555309A Active JP6959258B2 (ja) | 2016-01-08 | 2017-01-09 | 改変された腫瘍溶解性ウイルス |
| JP2021163811A Active JP7295192B2 (ja) | 2016-01-08 | 2021-10-05 | 改変された腫瘍溶解性ウイルス |
| JP2022034569A Pending JP2022078225A (ja) | 2016-01-08 | 2022-03-07 | 操作された腫瘍溶解性ウイルス |
| JP2023094818A Pending JP2023113885A (ja) | 2016-01-08 | 2023-06-08 | 改変された腫瘍溶解性ウイルス |
| JP2024119344A Pending JP2024153748A (ja) | 2016-01-08 | 2024-07-25 | 操作された腫瘍溶解性ウイルス |
| JP2025128636A Pending JP2025163138A (ja) | 2016-01-08 | 2025-07-31 | 改変された腫瘍溶解性ウイルス |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555311A Active JP7038664B2 (ja) | 2016-01-08 | 2017-01-09 | 操作された腫瘍溶解性ウイルス |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555309A Active JP6959258B2 (ja) | 2016-01-08 | 2017-01-09 | 改変された腫瘍溶解性ウイルス |
| JP2021163811A Active JP7295192B2 (ja) | 2016-01-08 | 2021-10-05 | 改変された腫瘍溶解性ウイルス |
| JP2022034569A Pending JP2022078225A (ja) | 2016-01-08 | 2022-03-07 | 操作された腫瘍溶解性ウイルス |
| JP2023094818A Pending JP2023113885A (ja) | 2016-01-08 | 2023-06-08 | 改変された腫瘍溶解性ウイルス |
| JP2024119344A Pending JP2024153748A (ja) | 2016-01-08 | 2024-07-25 | 操作された腫瘍溶解性ウイルス |
| JP2025128636A Pending JP2025163138A (ja) | 2016-01-08 | 2025-07-31 | 改変された腫瘍溶解性ウイルス |
Country Status (13)
| Country | Link |
|---|---|
| US (13) | US10570377B2 (enExample) |
| EP (8) | EP3400290B1 (enExample) |
| JP (8) | JP7038664B2 (enExample) |
| KR (2) | KR20250026348A (enExample) |
| CN (3) | CN109415703B (enExample) |
| AU (2) | AU2017205216B2 (enExample) |
| CA (3) | CA3011004A1 (enExample) |
| DK (4) | DK3400290T5 (enExample) |
| ES (4) | ES2943150T3 (enExample) |
| IL (2) | IL260480B (enExample) |
| MX (1) | MX2018008413A (enExample) |
| SG (2) | SG10202108724YA (enExample) |
| WO (4) | WO2017118864A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022002531A (ja) * | 2016-01-08 | 2022-01-11 | レプリミュン リミテッド | 改変された腫瘍溶解性ウイルス |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2254359T3 (es) * | 2000-01-21 | 2006-06-16 | Biovex Limited | Cepa viral para el tratamiento oncolitico de canceres. |
| EA016217B1 (ru) | 2005-12-02 | 2012-03-30 | Маунт Синай Скул Оф Медсин | Химерные вирусы, представляющие неприродные поверхностные белки, и их применение |
| JP2010529820A (ja) | 2007-05-31 | 2010-08-26 | クリシュナン ラム | 最小限の固定子鉄心を備えたスイッチドリラクタンス機 |
| CA2905272A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| BR112018000917A2 (pt) | 2015-07-16 | 2018-09-11 | Bioxcel Therapeutics Inc | abordagem inovadora para o tratamento de câncer através da imunomodulação |
| RU2021114137A (ru) | 2016-01-27 | 2021-05-25 | Онкорус, Инк. | Онколитические вирусные векторы и их применение |
| CA3010779A1 (en) | 2016-03-16 | 2017-09-21 | Amal Therapeutics Sa | Combination of an immune checkpoint modulator and a complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist for use in medicine |
| WO2017181420A1 (en) * | 2016-04-22 | 2017-10-26 | Immuno Vir Co., Limited | CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| US10888594B2 (en) | 2016-05-30 | 2021-01-12 | National University Corporation Tottori University | Genetically engineered vaccinia viruses |
| US20190336552A1 (en) | 2016-05-30 | 2019-11-07 | Astellas Pharma Inc. | Genetically engineered vaccinia viruses |
| RU2021127872A (ru) * | 2016-06-30 | 2021-11-09 | Онкорус, Инк. | Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов |
| DK3515476T3 (da) | 2016-09-21 | 2024-09-02 | Amal Therapeutics Sa | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer |
| CN108261426B (zh) * | 2017-01-04 | 2019-04-05 | 杭州康万达医药科技有限公司 | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 |
| GB201700350D0 (en) * | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| CN110678750A (zh) | 2017-04-28 | 2020-01-10 | 美国默沙东药厂 | 用于癌症治疗的生物标志物 |
| JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
| US11612625B2 (en) | 2017-07-26 | 2023-03-28 | Oncorus, Inc. | Oncolytic viral vectors and uses thereof |
| CR20200099A (es) | 2017-08-03 | 2020-07-24 | Amgen Inc | Muteínas de interleucina 21 y métodos de tratamiento |
| EP3679040B1 (en) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| CN109554353B (zh) * | 2017-09-26 | 2021-08-06 | 杭州康万达医药科技有限公司 | 分离的重组溶瘤痘病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| CN111542601A (zh) * | 2017-11-08 | 2020-08-14 | 国立大学法人鹿儿岛大学 | 确保安全并且能够有效地治疗甚至转移性癌症的、具有提供装载的免疫诱导基因的最佳表达水平的表达控制系统的肿瘤溶解性病毒(肿瘤溶解性免疫治疗) |
| JP2021502423A (ja) * | 2017-11-13 | 2021-01-28 | バイオエクセル セラピューティクス，インコーポレイテッド | 免疫系の複数のアームを修飾することによってがんを治療するための方法及び組成物 |
| EP3731850A4 (en) | 2017-12-29 | 2021-12-01 | Oncorus, Inc. | ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES |
| TW201930344A (zh) | 2018-01-12 | 2019-08-01 | 美商安進公司 | 抗ｐｄ-１抗體及治療方法 |
| EP3743095A1 (en) * | 2018-01-26 | 2020-12-02 | Celldex Therapeutics, Inc. | Methods of treating cancer with dendritic cell mobilizing agents |
| GB201804473D0 (en) * | 2018-03-21 | 2018-05-02 | Valo Therapeutics Oy | Modified oncolytic adenoviruses |
| CN108635380A (zh) * | 2018-04-13 | 2018-10-12 | 北京唯源立康生物科技有限公司 | 重组溶瘤病毒组合物及其在制备用于治疗肿瘤的药物中的应用 |
| WO2019243847A1 (en) * | 2018-06-21 | 2019-12-26 | Replimune Limited | Treatment using oncolytic virus |
| AU2019292580A1 (en) * | 2018-06-29 | 2021-02-04 | Krystal Biotech, Inc. | Compositions and methods for antibody delivery |
| CN109161561A (zh) * | 2018-08-09 | 2019-01-08 | 湖北科技学院 | 一种选择性杀灭前列腺癌细胞的新型溶瘤病毒及其构建方法 |
| WO2020037215A1 (en) | 2018-08-17 | 2020-02-20 | Icahn School Of Medicine At Mount Sinai | Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease |
| JP2022502074A (ja) * | 2018-09-10 | 2022-01-11 | ジェネセイル バイオテック（シャンハイ）カンパニー リミテッド | 改変された腫瘍溶解性ウイルス、組成物、およびその使用 |
| MX2021003539A (es) | 2018-09-26 | 2021-05-27 | Astellas Pharma Inc | Terapia contra el cancer en donde el virus vaccinia oncolitico e inhibidor de punto de control inmunitario se usan en combinacion, y composicion farmaceutica y medicamento de combinacion usado en ella. |
| WO2020140012A1 (en) | 2018-12-27 | 2020-07-02 | Amgen Inc. | Lyophilized virus formulations |
| CN111606999B (zh) * | 2019-02-26 | 2022-09-06 | 南京惟亚德生物医药有限公司 | 兼具激活免疫共刺激信号通路和阻断免疫检查点的复制型溶瘤腺病毒及其应用 |
| BR112021017551A2 (pt) * | 2019-03-05 | 2021-11-09 | Amgen Inc | Uso de vírus oncolíticos para o tratamento de câncer |
| TW202102543A (zh) | 2019-03-29 | 2021-01-16 | 美商安進公司 | 溶瘤病毒在癌症新輔助療法中之用途 |
| CN110054678B (zh) * | 2019-05-16 | 2023-04-18 | 中国医学科学院血液病医院（血液学研究所） | 一种膜结合型mFLT3LG蛋白及其应用 |
| CN110218707B (zh) * | 2019-05-29 | 2021-10-22 | 上海市公共卫生临床中心 | 一种新型溶瘤病毒及其制备方法和应用 |
| JPWO2021024897A1 (enExample) * | 2019-08-05 | 2021-02-11 | ||
| US11951141B2 (en) * | 2019-11-06 | 2024-04-09 | Memgen, Inc. | Replication-enhanced oncolytic adenoviruses |
| US20240216533A1 (en) * | 2020-03-05 | 2024-07-04 | Beijing Wellgene Company Ltd. | Herpes simplex virus and use thereof |
| CN110982794B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种修饰的单纯疱疹病毒 |
| CN110982795B (zh) * | 2020-03-05 | 2020-06-16 | 北京唯源立康生物科技有限公司 | 一种单纯疱疹病毒及其用途 |
| WO2021193081A1 (ja) * | 2020-03-23 | 2021-09-30 | 国立大学法人東海国立大学機構 | １型単純ヘルペスウイルス |
| CA3184366A1 (en) | 2020-06-29 | 2022-01-06 | Darby Rye Schmidt | Viruses engineered to promote thanotransmission and their use in treating cancer |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| CN112941039A (zh) * | 2021-02-01 | 2021-06-11 | 南京大学 | 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用 |
| DE102022104146A1 (de) | 2021-03-19 | 2022-09-22 | Yamada Manufacturing Co., Ltd. | Lenkvorrichtung |
| AU2022255538A1 (en) * | 2021-04-08 | 2023-09-28 | Immvira Biopharmaceuticals Co., Limited | Genetically modified oncolytic herpes simplex virus delivering chemokine and tumor associated/specific antigen |
| WO2022245808A1 (en) * | 2021-05-18 | 2022-11-24 | The Penn State Research Foundation | Oncolytic virus based cancer therapy |
| CN113583979B (zh) * | 2021-08-03 | 2022-11-22 | 杭州荣谷生物科技有限公司 | 一种重组溶瘤痘苗病毒、制备方法及其用途 |
| JPWO2023136212A1 (enExample) | 2022-01-11 | 2023-07-20 | ||
| WO2024055022A2 (en) * | 2022-09-08 | 2024-03-14 | Virogin Biotech Canada Ltd | Oncolytic virus expressing an immune cell engager for tumor targeting |
| WO2025248110A1 (en) * | 2024-05-31 | 2025-12-04 | Replimune Limited | An oncolytic herpes simplex virus (hsv) and an anti-pd-1 antibody for use in treating braf mutant melanoma |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| JP2006528484A (ja) | 2003-07-25 | 2006-12-21 | バイオヴェックス リミテッド | ウイルスベクター |
| JP2019501670A (ja) | 2016-01-08 | 2019-01-24 | レプリミュン リミテッド | 改変された腫瘍溶解性ウイルス |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU594014B2 (en) | 1984-03-21 | 1990-03-01 | Research Corporation Technologies, Inc. | Recombinant DNA molecules |
| CA1282721C (en) | 1984-06-04 | 1991-04-09 | Bernard Roizman | Herpes simplex virus as a vector |
| US5288641A (en) | 1984-06-04 | 1994-02-22 | Arch Development Corporation | Herpes Simplex virus as a vector |
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5698531A (en) | 1989-03-31 | 1997-12-16 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5328688A (en) | 1990-09-10 | 1994-07-12 | Arch Development Corporation | Recombinant herpes simplex viruses vaccines and methods |
| US6770274B1 (en) | 1990-09-14 | 2004-08-03 | The General Hospital Corporation | Viral mutant HSV mediated destruction of neoplastic cells |
| US6040169A (en) | 1991-01-31 | 2000-03-21 | Medical Research Council | Herpes simplex virus-1 deletion variants and vaccines thereof |
| DE69332525T2 (de) | 1992-03-31 | 2003-04-17 | Arch Development Corp., Chicago | Behandlung von Tumorerkrankungen mit modifiziertem HSV |
| US6699468B1 (en) | 1994-06-23 | 2004-03-02 | Georgetown University | Replication-competent herpes simplex virus mediates destruction of neoplastic cells |
| CA2234060A1 (en) | 1995-10-06 | 1997-04-10 | Arch Development Corporation | Methods and compositions for viral enhancement of cell killing |
| US5824318A (en) | 1996-07-24 | 1998-10-20 | American Cyanamid Company | Avirulent herpetic viruses useful as tumoricidal agents and vaccines |
| GB9700411D0 (en) | 1997-01-10 | 1997-02-26 | Univ London | Eukaryotic gene expression cassette and uses thereof |
| US6379674B1 (en) | 1997-08-12 | 2002-04-30 | Georgetown University | Use of herpes vectors for tumor therapy |
| US7300774B1 (en) | 1999-12-09 | 2007-11-27 | The Regents Of The University Of California | Multimeric fusion proteins of the TNF superfamily ligands |
| US6428968B1 (en) | 1999-03-15 | 2002-08-06 | The Trustees Of The University Of Pennsylvania | Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject |
| EP1227828A1 (en) | 1999-11-12 | 2002-08-07 | Oncolytics Biotech, Inc. | Viruses for the treatment of cellular proliferative disorders |
| ES2254359T3 (es) | 2000-01-21 | 2006-06-16 | Biovex Limited | Cepa viral para el tratamiento oncolitico de canceres. |
| EP1381280B1 (en) | 2001-03-27 | 2011-05-11 | Catherex, Inc. | Viral vectors and their use in therapeutic methods |
| KR20070067702A (ko) | 2004-11-04 | 2007-06-28 | 화이자 프로덕츠 인크. | 유방암을 치료하기 위한 ｃｔｌａ-4 항체와 아로마타제억제제 병용 요법 |
| US9866961B2 (en) | 2004-12-01 | 2018-01-09 | Todd Beauchamp | Multi-channel loudspeaker enclosure with laterally projecting wings and method for orienting and driving multiple loudspeakers |
| AR054233A1 (es) | 2005-03-08 | 2007-06-13 | Pharmacia & Upjohn Co Llc | Composiciones de anticuerpos igg2 |
| PT1877090E (pt) | 2005-05-06 | 2014-04-15 | Providence Health System | Proteína de fusão trimérica de imunoglobulina-ox40 e métodos de utilização |
| CN101495126B (zh) | 2005-06-23 | 2016-01-06 | 休斯顿大学 | Ⅱ型单纯疱疹病毒突变体在治疗癌症中的用途 |
| GB0522476D0 (en) | 2005-11-03 | 2005-12-14 | Biovex Ltd | Oncolytic herpes virus vectors |
| EP2013348A4 (en) | 2006-03-30 | 2009-09-02 | Univ California | METHOD AND COMPOSITIONS FOR LOCALIZED SECRETION OF ANTI-CTLA-4 ANTIBODIES |
| US8313896B2 (en) * | 2008-04-04 | 2012-11-20 | The General Hospital Corporation | Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer |
| WO2009148488A2 (en) | 2008-05-29 | 2009-12-10 | The General Hospital Corporation | Use of oncolytic herpes viruses for killing cancer stem cells |
| BRPI0920679A2 (pt) | 2008-10-08 | 2022-05-17 | Intrexon Corp | Células construídas expressando múltiplos imunomoduladores e usos das mesmas |
| US20100297072A1 (en) | 2009-05-19 | 2010-11-25 | Depinho Ronald A | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy |
| EP2502078A1 (en) | 2009-11-20 | 2012-09-26 | Infinity Pharmaceuticals, Inc. | Methods and compositions for treating hedgehog-associated cancers |
| WO2011119925A2 (en) * | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| WO2011118866A1 (ko) | 2010-03-26 | 2011-09-29 | 연세대학교 산학협력단 | 네트워크를 통한 심사요청 방법 |
| CA2812093A1 (en) * | 2010-09-24 | 2012-03-29 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - ctla - 4 antibodies |
| PL2753355T3 (pl) * | 2011-09-08 | 2019-04-30 | Benevir Biopharm Inc | Onkolityczny wirus opryszczki pospolitej i jego zastosowania lecznicze |
| FI20115914A7 (fi) | 2011-09-16 | 2013-03-17 | Oncos Therapeutics Ltd | Muunnettu onkolyyttinen virus |
| WO2013112942A1 (en) | 2012-01-25 | 2013-08-01 | Dna Trix, Inc. | Biomarkers and combination therapies using oncolytic virus and immunomodulation |
| EP2879498A4 (en) | 2012-07-30 | 2016-03-30 | Alex Wah Hin Yeung | BY TREATMENT OF AT LEAST TWO OR ALL THREE OF THE FOLLOWING COMPONENTS SUCH AS TUMOR CELLS, AN ONCOLYTIC VIRUS VECTOR WITH TRANSGENIC EXPRESSION OF GM-CSF AND AN IMMUNE TEST MODULE DEVELOPED TUMOR SPECIFIC LIVING AND IN VIVO CANCER VACCINE SYSTEM |
| CN104704002B (zh) | 2012-08-30 | 2022-05-10 | 安姆根有限公司 | 使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法 |
| EP2912063A1 (en) | 2012-10-23 | 2015-09-02 | Bristol-Myers Squibb Company | Combination of anti-kir and anti-ctla-4 antibodies to treat cancer |
| HK1211235A1 (en) | 2013-02-22 | 2016-05-20 | 霍夫曼-拉罗奇有限公司 | Methods of treating cancer and preventing drug resistance |
| CA2905272A1 (en) | 2013-03-14 | 2014-10-02 | Icahn School Of Medicine At Mount Sinai | Newcastle disease viruses and uses thereof |
| WO2015032755A1 (en) | 2013-09-03 | 2015-03-12 | Medimmune Limited | Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia |
| NO3021859T3 (enExample) | 2013-10-25 | 2018-04-28 | ||
| EP3184641B1 (en) | 2013-10-28 | 2020-07-08 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Oncolytic hsv vector |
| AU2014352749A1 (en) | 2013-11-22 | 2016-06-09 | Dnatrix, Inc. | Adenovirus expressing immune cell stimulatory receptor agonist(s) |
| WO2015128313A1 (en) | 2014-02-25 | 2015-09-03 | Deutsches Krebsforschungszentrum | Rna viruses for immunovirotherapy |
| MA39818A (fr) * | 2014-03-30 | 2017-02-08 | Benevir Biopharm Inc | Virus oncolytiques « armés » comprenant un inhibiteur de tap exogène et leurs utilisations thérapeutiques |
| DK3169340T3 (da) | 2014-07-16 | 2020-11-09 | Roussy Inst Gustave | Kombination af onkolytisk virus med immun-checkpoint-modulatorer |
| EP3552615B8 (en) | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
| US20160040186A1 (en) | 2014-08-07 | 2016-02-11 | Xiaoyun Liu | Dna construct and method for transgene expression |
| GB201419579D0 (en) | 2014-11-03 | 2014-12-17 | Iomet Pharma Ltd | Pharmaceutical compound |
| EP3247672B1 (en) | 2015-01-23 | 2018-11-28 | Dreamwell, Ltd. | Automated mattress manufacturing process and apparatus |
| WO2017181420A1 (en) | 2016-04-22 | 2017-10-26 | Immuno Vir Co., Limited | CONSTRUCTION OF ONCOLYTIC HERPES SIMPLEX VIRUSES (oHSV) OBLIGATE VECTOR AND CONSTRUCTS FOR CANCER THERAPY |
| GB201700350D0 (en) | 2017-01-09 | 2017-02-22 | Replimune Ltd | Altered virus |
| US12029647B2 (en) * | 2017-03-07 | 2024-07-09 | 4C Medical Technologies, Inc. | Systems, methods and devices for prosthetic heart valve with single valve leaflet |
| WO2019243847A1 (en) | 2018-06-21 | 2019-12-26 | Replimune Limited | Treatment using oncolytic virus |
| WO2020124273A1 (en) | 2018-12-21 | 2020-06-25 | Ottawa Hospital Research Institute | Modified orthopoxvirus vectors |
-
2017
- 2017-01-09 CN CN201780012527.8A patent/CN109415703B/zh active Active
- 2017-01-09 CN CN201780012579.5A patent/CN109312309B/zh active Active
- 2017-01-09 US US16/068,826 patent/US10570377B2/en active Active
- 2017-01-09 JP JP2018555311A patent/JP7038664B2/ja active Active
- 2017-01-09 DK DK17700384.5T patent/DK3400290T5/da active
- 2017-01-09 ES ES17700384T patent/ES2943150T3/es active Active
- 2017-01-09 ES ES20197725T patent/ES3041885T3/es active Active
- 2017-01-09 MX MX2018008413A patent/MX2018008413A/es unknown
- 2017-01-09 AU AU2017205216A patent/AU2017205216B2/en active Active
- 2017-01-09 CA CA3011004A patent/CA3011004A1/en active Pending
- 2017-01-09 WO PCT/GB2017/050036 patent/WO2017118864A1/en not_active Ceased
- 2017-01-09 EP EP17700384.5A patent/EP3400290B1/en active Active
- 2017-01-09 WO PCT/GB2017/050037 patent/WO2017118865A1/en not_active Ceased
- 2017-01-09 WO PCT/GB2017/050038 patent/WO2017118866A1/en not_active Ceased
- 2017-01-09 SG SG10202108724YA patent/SG10202108724YA/en unknown
- 2017-01-09 JP JP2018555310A patent/JP7038065B2/ja active Active
- 2017-01-09 EP EP17701910.6A patent/EP3400293B2/en active Active
- 2017-01-09 SG SG11201805835WA patent/SG11201805835WA/en unknown
- 2017-01-09 DK DK17701910.6T patent/DK3400293T4/da active
- 2017-01-09 CA CA3011009A patent/CA3011009A1/en active Pending
- 2017-01-09 US US16/068,830 patent/US10947513B2/en active Active
- 2017-01-09 EP EP20189881.4A patent/EP3778881A1/en active Pending
- 2017-01-09 CA CA3010987A patent/CA3010987A1/en active Pending
- 2017-01-09 WO PCT/GB2017/050039 patent/WO2017118867A1/en not_active Ceased
- 2017-01-09 DK DK20197725.3T patent/DK3805376T3/da active
- 2017-01-09 DK DK17700385.2T patent/DK3400291T4/da active
- 2017-01-09 EP EP25185492.3A patent/EP4628577A2/en active Pending
- 2017-01-09 CN CN201780012759.3A patent/CN109153977B/zh active Active
- 2017-01-09 ES ES17700385T patent/ES2841300T5/es active Active
- 2017-01-09 EP EP17700385.2A patent/EP3400291B2/en active Active
- 2017-01-09 EP EP23156055.8A patent/EP4219696A3/en active Pending
- 2017-01-09 KR KR1020257002985A patent/KR20250026348A/ko active Pending
- 2017-01-09 ES ES17701910T patent/ES2831080T5/es active Active
- 2017-01-09 EP EP17700386.0A patent/EP3400292B1/en active Active
- 2017-01-09 KR KR1020187022799A patent/KR102762431B1/ko active Active
- 2017-01-09 US US16/068,816 patent/US10612005B2/en active Active
- 2017-01-09 JP JP2018555309A patent/JP6959258B2/ja active Active
- 2017-01-09 US US16/068,823 patent/US10626377B2/en active Active
- 2017-01-09 EP EP20197725.3A patent/EP3805376B1/en active Active
-
2018
- 2018-07-08 IL IL260480A patent/IL260480B/en active IP Right Grant
-
2020
- 2020-01-10 US US16/740,203 patent/US11473063B2/en active Active
- 2020-02-24 US US16/799,090 patent/US11427810B2/en active Active
-
2021
- 2021-02-01 US US17/164,635 patent/US12049647B2/en active Active
- 2021-05-06 IL IL282985A patent/IL282985B/en unknown
- 2021-10-05 JP JP2021163811A patent/JP7295192B2/ja active Active
-
2022
- 2022-03-07 JP JP2022034569A patent/JP2022078225A/ja active Pending
- 2022-08-03 US US17/817,245 patent/US12458696B2/en active Active
- 2022-08-04 US US17/817,618 patent/US12024724B2/en active Active
- 2022-12-01 AU AU2022279486A patent/AU2022279486B2/en active Active
-
2023
- 2023-02-02 US US18/163,837 patent/US12397053B2/en active Active
- 2023-06-08 JP JP2023094818A patent/JP2023113885A/ja active Pending
- 2023-09-06 US US18/462,133 patent/US12465639B2/en active Active
-
2024
- 2024-05-21 US US18/670,296 patent/US20240301365A1/en active Pending
- 2024-07-25 JP JP2024119344A patent/JP2024153748A/ja active Pending
-
2025
- 2025-07-23 US US19/277,600 patent/US20250352646A1/en active Pending
- 2025-07-31 JP JP2025128636A patent/JP2025163138A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006528484A (ja) | 2003-07-25 | 2006-12-21 | バイオヴェックス リミテッド | ウイルスベクター |
| WO2006002394A2 (en) | 2004-06-24 | 2006-01-05 | New York University | Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response |
| JP2019501670A (ja) | 2016-01-08 | 2019-01-24 | レプリミュン リミテッド | 改変された腫瘍溶解性ウイルス |
| JP2019501671A (ja) | 2016-01-08 | 2019-01-24 | レプリミュン リミテッド | 操作された腫瘍溶解性ウイルス |
Non-Patent Citations (4)
| Title |
|---|
| Cancer Research，2006年，Vol.66, No.9，p.4835-4842 |
| Gene Therapy，2003年，Vol.10, No.4，p.292-303 |
| Journal of Clinical Oncology，2009年，Vol.27, No.34，p.5763-5771 |
| Oncolytic Virotherapy，2015年，Vol.4，p.207-219 |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022002531A (ja) * | 2016-01-08 | 2022-01-11 | レプリミュン リミテッド | 改変された腫瘍溶解性ウイルス |
| JP2022078225A (ja) * | 2016-01-08 | 2022-05-24 | レプリミュン リミテッド | 操作された腫瘍溶解性ウイルス |
| JP7295192B2 (ja) | 2016-01-08 | 2023-06-20 | レプリミュン リミテッド | 改変された腫瘍溶解性ウイルス |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12458696B2 (en) | Modified oncolytic virus | |
| JP2021527694A (ja) | 腫瘍溶解性ウイルスを用いた処置 | |
| HK40088422A (en) | Oncolytic virus strain | |
| HK40045432A (en) | Modified oncolytic virus | |
| HK1257074B (en) | Oncolytic virus strain |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20190611 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190611 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191212 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201127 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201216 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210316 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210824 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211117 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220208 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220307 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7038065 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |